8 completed, 2 recruiting, 2 terminated, 1 withdrawn. 13 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 8, Recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 7 | Completed 5, Recruiting 1, Terminated 1 |
Follow Hyperoxaluria: new trials by email Literature Review of Hyperoxaluria trials Research Report on Hyperoxaluria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1) YOLT-203 - Primary Hyperoxaluria Type 1, PH1 | Phase 1 | Recruiting | YolTech Therapeutics Co., Ltd | 9 | 2026-08-01 | 2026-08-20 |
| Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine) ABO-101 - Primary Hyperoxaluria Type 1 (PH1) | Phase 1 / Phase 2 | Recruiting | Arbor Biotechnologies | 23 | 2025-06-16 | 2026-10-19 |
| A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria BMN 255, Placebo - Hyperoxaluria, Nonalcoholic Fatty Liver Disease | Phase 1 | Withdrawn | BioMarin Pharmaceutical | 2023-09-26 | 2024-06-11 | |
| Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects NOV-001, NB1000S, NB2000P - Healthy Volunteers, Enteric Hyperoxaluria | Phase 1 / Phase 2 | Terminated | Novome Biotechnologies Inc | 153 | 2021-06-02 | 2023-05-17 |
| Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients DCR-PHXC, Sterile Normal Saline (0.9% NaCl) - Primary Hyperoxaluria Type 3 | Phase 1 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 6 | 2020-09-14 | 2024-09-19 |
| Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria DCR-PHXC, Placebo - Primary Hyperoxaluria | Phase 1 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 43 | 2017-12-06 | 2024-09-19 |
| A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1) DCR-PH1, Placebo - Primary Hyperoxaluria Type 1 | Phase 1 | Terminated | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 41 | 2016-05-13 | 2024-07-11 |
| Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1 Lumasiran, Placebo - Primary Hyperoxaluria Type 1 (PH1) | Phase 1 / Phase 2 | Completed | Alnylam Pharmaceuticals | 52 | 2016-03-08 | 2020-01-30 |
| Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria Oxabact OC5 capsules, Placebo capsules - Primary Hyperoxaluria | Phase 1 / Phase 2 | Completed | OxThera | 28 | 2013-12-01 | 2015-10-16 |
| Hydroxyproline Influence on Oxalate Metabolism Hydroxyproline and Leucine - Hyperoxaluria | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2013-09-01 | 2017-07-02 |
| Oxazyme in Patients With Hyperoxaluria Oxazyme - Hyperoxaluria | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2010-05-01 | 2012-12-24 |
| Use of Oral Probiotics to Reduce Urinary Oxalate Excretion Oxadrop, Agri-King Synbiotic (AKSB), Placebo - Nephrolithiasis, Hyperoxaluria | Phase 1 / Phase 2 | Completed | Mayo Clinic | 40 | 2006-02-01 | 2012-05-31 |
| Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria C-13 labeled oxalate - Enteric Hyperoxaluria, Hyperoxaluria | Phase 1 | Completed | Mayo Clinic | 114 | 1998-12-01 | 2020-03-03 |
Hyperoxaluria, Primary (7) · Kidney Calculi (5) · Primary hyperoxaluria type 1 (4) · Calculi (1) · Crohn Disease (1) · Genetic Diseases, Inborn (1) · Metabolic Diseases (1) · Nephrolithiasis (1) · Non-alcoholic Fatty Liver Disease (1) · Urologic Diseases (1)
Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Kidney Diseases (13) · Male Urogenital Diseases (13) · Urogenital Diseases (13) · Urologic Diseases (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Nutritional and Metabolic Diseases (8) · Carbohydrate Metabolism, Inborn Errors (7) · Genetic Diseases, Inborn (7) · Metabolic Diseases (7) · Metabolism, Inborn Errors (7) · Pathological Conditions, Anatomical (5) · Pathological Conditions, Signs and Symptoms (5) · Urinary Calculi (5)
Hydroxyproline (1) · Leucine (1) · Oxalates (1) · lumasiran (1) · nedosiran (1) · oxalate decarboxylase (1)
Mayo Clinic (4) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (3) · Alnylam Pharmaceuticals (1) · Arbor Biotechnologies (1) · BioMarin Pharmaceutical (1) · Novome Biotechnologies Inc (1) · OxThera (1) · YolTech Therapeutics Co., Ltd (1)
United States (9) · Germany (6) · United Kingdom (5) · France (4) · Netherlands (4) · Canada (1) · China (1) · Israel (1) · Tunisia (1)
John C Lieske, MD (2) · Alexandra Haagensen, MD, MBA (1) · Bernd Hoppe, MD PhD (1) · Daniel Ory, MD (1) · Dawn Milliner (1) · John Lieske, MD (1) · Lachy McLean, MB ChB, PhD (1) · Tracy McGregor, MD, MSCI (1)
PMID 20736987, PMID 33985991, PMID 40601241, PMID 41388232
U54DK083908 (2), 2015 (1), P50DK083007 (1), R21AT002534 (1), UL1RR024150 (1)